The battle between ultrasound contrast companies over patents continues to rage on. Molecular Biosystems has announced that it received notice from the U.S. Patent Office (PTO) that the firm's petitions seeking reexamination of two patents held by rival
The battle between ultrasound contrast companies over patents continues to rage on. Molecular Biosystems has announced that it received notice from the U.S. Patent Office (PTO) that the firm's petitions seeking reexamination of two patents held by rival ImaRx Pharmaceuticals have been granted. The PTO will subject all claims of the ImaRx patents to reconsideration as to whether any of those claims are patentable, according to San Diego-based MBI.
The PTO said that it will review certain prior-art references brought to the PTO's attention in MBI's reexamination petitions, according to MBI. The key prior-art references include several that ImaRx did not disclose to the PTO during prosecution of the Tucson, AZ-based company's patent applications, MBI said. The PTO orders state that specific references raise substantial new questions concerning the patentability of the ImaRx patent claims, according to MBI.
The Reading Room: Racial and Ethnic Minorities, Cancer Screenings, and COVID-19
November 3rd 2020In this podcast episode, Dr. Shalom Kalnicki, from Montefiore and Albert Einstein College of Medicine, discusses the disparities minority patients face with cancer screenings and what can be done to increase access during the pandemic.
Study Finds Transvaginal Ultrasound Unreliable for Detecting Endometrial Cancer in Black Patients
July 3rd 2024Utilizing a threshold of less than 5 mm of ultrasound-measured endometrial thickness, the authors of a new study noted an 11.4 percent false-negative probability for endometrial cancer in Black patients.
New Study Shows Non-Radiologists Interpreting 28 Percent of Imaging for Medicare Patients
June 28th 2024While radiologists interpreted approximately 99 percent of all non-cardiac CT, MRI and nuclear medicine studies in hospital and emergency department settings for Medicare beneficiaries, new research shows significantly less radiologist review of cardiac imaging and office-based imaging.
FDA Clears Pocket-Sized ECG System and AI Technology for Detection of Cardiac Conditions
June 27th 2024Using a reduced leadset and deep neural network algorithms trained on more than 175 million electrocardiograms, the KAI 12L technology reportedly detects up to 35 cardiac determinations, including acute myocardial infarction.